Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.

Nuala Ann Helsby Minghan Yong Kathryn Elisa Burns Michael P N Findlay David Porter

Published in: Cancer chemotherapy and pharmacology (2021)

Comedications may be the cause for this inter-occasion variation in bioactivation of cyclophosphamide and the ensuing phenoconversion may account for the conflicting reports in the literature about the relationship between CYP2C19 genotype and CP bioactivation pharmacokinetics. Trial registration ANZCTR363222 (6/11/2012, retrospectively registered).

Keyphrases

high dose
low dose
systematic review
study protocol
clinical trial
phase iii
phase ii
randomized controlled trial
adverse drug
open label